# Single and Multiple Ascending Dose Study in Healthy Participants and Participants With an Autoimmune Disease

> **NCT06488209** · PHASE1 · COMPLETED · sponsor: **Almirall, S.A.** · enrollment: 69 (actual)

## Conditions studied

- Healthy Volunteers
- Autoimmune Disease

## Interventions

- **DRUG:** LAD191
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT06488209
- **Lead sponsor:** Almirall, S.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-07-29
- **Primary completion:** 2025-04-03
- **Final completion:** 2025-04-03
- **Target enrollment:** 69 (ACTUAL)
- **Last updated:** 2025-11-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06488209

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06488209, "Single and Multiple Ascending Dose Study in Healthy Participants and Participants With an Autoimmune Disease". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT06488209. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*